← 返回

免疫微环境和基因组改变决定三阴性乳腺癌免疫调节亚型肿瘤行为

英文原题:Immune Milieu and Genomic Alterations Set the Triple-Negative Breast Cancer Immunomodulatory Subtype Tumor Behavior.

查看英文原题

Immune Milieu and Genomic Alterations Set the Triple-Negative Breast Cancer Immunomodulatory Subtype Tumor Behavior.

PubMed 2021/12/13(内容时间) Cancers (Basel) Q2 · IF 4.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

IM 亚型显示出独特的免疫微环境,以及亚型特异性的基因组改变。在分子和转录组水平上对 TNBC 进行表征可能有助于指导该患者亚组的免疫治疗。

研究思路结论见上方概要

对68例高危(III-IV期)TNBC患者的福尔马林固定石蜡包埋肿瘤样本进行了微阵列、免疫组化和DNA测序分析。

在24%的TNBC肿瘤样本中鉴定出IM亚型,与非IM亚型相比,其特征为FOXP3+ TILs(Treg)在瘤内(intT)和间质(strml)的浸润更高。此外,IM亚型中PD-L1+(>1%)表达显著更高,CTLA-4+ intT和strml表达也显著更高。差异表达和基因集富集分析鉴定出与免疫系统相关的生物学过程。通路分析揭示β-catenin信号通路富集。非编码分析得出7个长基因间非蛋白编码RNA(lincRNAs)(6个上调,1个下调),它们与TNBC-IM亚型的良好预后相关。DNA测序突出了两个与免疫系统反应相关的基因:CTNNB1(Catenin β-1)和IDH1。

展开英文摘要原文

Formalin-fixed paraffin-embedded tumor samples from 68 high-risk (stage III-IV) TNBC patients were analyzed through microarrays, immunohistochemistry, and DNA sequencing.

The IM subtype was identified in 24% of TNBC tumor samples and characterized by a higher intratumoral (intT) and stromal (strml) infiltration of FOXP3+ TILs (Treg) compared with non-IM subtypes. Further, PD-L1+ (>1%) expression was significantly higher, as well as CTLA-4+ intT and strml expression in the IM subtype. Differential expression and gene set enrichment analysis identified biological processes associated with the immune system. Pathway analysis revealed enrichment of the β-catenin signaling pathway. The non-coding analysis led to seven Long Intergenic Non-Protein Coding RNAs (lincRNAs) (6 up-regulated and 1 down-regulated) that were associated with a favorable prognosis in the TNBC-IM subtype. The DNA sequencing highlighted two genes relevant to immune system responses: CTNNB1 (Catenin β-1) and IDH1 .

the IM subtype showed a distinct immune microenvironment, as well as subtype-specific genomic alterations. Characterizing TNBC at a molecular and transcriptomic level might guide immune-based therapy in this subgroup of patients.

论文信息

作者
Rodríguez-Bautista R、Caro-Sánchez CH、Cabrera-Galeana P、Alanis-Funes GJ、Gutierrez-Millán E、Ávila-Ríos S、Matías-Florentino M、Reyes-Terán G
单位
Laboratorio de Medicina Personalizada de la Unidad de Oncología Torácica, Instituto Nacional de Cancerología (INCan), Mexico City 14080, Mexico.Mexico
期刊
Cancers2021 Dec 13
原文标识
PubMed 34944876 · DOI 10.3390/cancers13246256